Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Develop Healthy Habits Our experts provide guidance for your diet and exercise routine to promote long-term health following your treatment
Participants receiving the 5mg dose achieved an average 16.0% body weight reduction
The candidate previously demonstrated promising weight loss outcomes in Phase 2 trials, and its progression into late-stage testing underscores the competitive momentum building in this high-growth therapeutic category In January 2024, Zealand Pharma and Boehringer Ingelheim announced positive Phase 2 results for BI 456906, a long-acting GLP-1/glucagon dual agonist, in obese individuals
Shake mixes
These innovative treatments work by regulating blood sugar and suppressing appetite through their interaction with GLP-1 hormones, making them a powerful solution for sustained weight loss success
